Development and validation of a patient derived xenograft based preclinical platform for immuno-oncology drug development

被引：0
|
作者：
Oswald, E. [1 ]
Grote, A. [2 ]
Bug, D. [3 ]
Loehr, A. [1 ]
Lenhardt, D. [1 ]
Niedermann, G. [4 ]
Merhof, D. [3 ]
Feuerhake, F. [2 ]
Schueler, J. [1 ]
机构：
[1] Oncotest GmbH, In Vivo Tumorbiol, Freiburg, Germany
[2] Hannover Med Sch, Inst Pathol, Hannover, Germany
[3] Rhein Westfal TH Aachen, LfB, Aachen, Germany
[4] Univ Freiburg, Med Ctr, Dept Radiat Oncol, Freiburg, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32920-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
326
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [1] New patient derived lymphoma xenograft (PDX) panel for drug development, immuno-oncology and translational research
    Brzezicha, B.
    Becker, M.
    Stecklum, M.
    Conrad, T.
    Janz, M.
    Bittner, A.
    Schmitt, C. A.
    Hoffmann, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S41 - S41
  • [2] Development and validation of a screening platform for the identification of novel immuno-oncology targets
    Scoumanne, Ariane
    Rabolli, Virginie
    Legrand, Lea
    Martini, Murielle
    Letellier, Marie-Claire
    Crosignani, Stefano
    Queva, Christophe
    Detheux, Michel
    Cauwenberghs, Sandra
    Swiercz, Jakub
    CANCER RESEARCH, 2017, 77
  • [3] New patient-derived head and neck cancer xenograft (PDX) panel for drug development, immuno-oncology and translational research
    Brzezicha, Bernadette
    Conrad, Theresia
    Stecklum, Maria
    Becker, Michael
    Klinghammer, Konrad
    Hoffmann, Jens
    CLINICAL CANCER RESEARCH, 2023, 29 (18)
  • [4] The immuno-AVI-PDX, am innovative patient-derived xenograft model for preclinical immuno-oncology studies
    Lacourrege, Marjorie
    Costechareyre, Clelia
    Jarrosson, Loraine
    Teinturier, Romain
    Berget, Frederic
    Delloye-Bourgeois, Celine
    Castellani, Valerie
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Development and validation of a phenotypic screening platform for the identification of novel immuno-oncology targets
    Rabolli, Virginie
    Martini, Murielle
    Scoumanne, Ariane
    Letellier, Marie-Claire
    Crosignani, Stefano
    Queva, Christophe
    Detheux, Michel
    Swiercz, Jakub M.
    Cauwenberghs, Sandra
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [6] Immuno-oncology drug development goes global
    Yu, Jia Xin
    Hubbard-Lucey, Vanessa M.
    Tang, Jun
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (12) : 899 - 900
  • [7] Lights and Shadows in Immuno-Oncology Drug Development
    Bergamino Sirven, Milana
    Pernas, Sonia
    Cheang, Maggie C. U.
    CANCERS, 2021, 13 (04) : 1 - 11
  • [8] Development of patient-derived xenograft (PDX) models for pancreatic carcinoma as a preclinical platform for drug development
    Ricono, Jill
    Thatte, Jayant
    Scott, Colleen
    Broudy, Thomas B.
    CANCER RESEARCH, 2016, 76
  • [9] Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immuno-oncology and translational research
    Alcaniz, Joshua
    Winkler, Lars
    Stecklum, Maria
    Wieland, Hagen
    Siegert, Antje
    Becker, Michael
    Brzezicha, Bernadette
    Walther, Wolfgang
    Hoffmann, Jens
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Preclinical models of patient derived xenografts (PDX) for immuno-oncology research
    Stecklum, M.
    Wulf-Goldenberg, A.
    Brzezicha, B.
    Fichtner, I.
    Hoffmann, J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S59 - S60
12345